Aerami Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aerami Therapeutics's estimated annual revenue is currently $3.1M per year.
- Aerami Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Aerami Therapeutics has 20 Employees.
- Aerami Therapeutics grew their employee count by 11% last year.
Aerami Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | VP Finance | Reveal Email/Phone |
5 | SVP, Clinical Development & Operations | Reveal Email/Phone |
6 | Director Operations | Reveal Email/Phone |
7 | Director & Chairman the Finance Committee | Reveal Email/Phone |
Aerami Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is Aerami Therapeutics?
Aerami Therapeutics is developing a new generation of inhaled therapies for the treatment of severe respiratory and chronic diseases. Our platform is designed to overcome the limitations of injectable, oral, and other inhaled formulation technologies for managing severe respiratory and chronic diseases. Ultimately, our aim is to improve treatment efficacy and improve patient lives. To learn more, visit: https://aerami.com/
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.9M | 20 | -29% | N/A |
#2 | $2M | 20 | -5% | N/A |
#3 | $4.1M | 20 | 11% | N/A |
#4 | $2M | 20 | -17% | N/A |
#5 | $4.3M | 21 | -28% | N/A |